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Abstract
Background: Secretory pituitary adenomas are very common brain tumors. Historically, the
treatment armamentarium for secretory pituitary adenomas included neurosurgery, medical
management, and fractionated radiotherapy. In recent years, MASEP gamma knife radiosurgery
(MASEP GKRS) has emerged as an important treatment modality in the management of secretory
pituitary adenomas. The goal of this research is to define accurately the efficacy, safety,
complications, and role of MASEP GKRS for treatment of secretory pituitary adenomas.
Methods: Between 1997 and 2007 a total of 347 patients with secretory pituitary adenomas
treated with MASEP GKRS and with at least 60 months of follow-up data were identified. In 47 of
these patients some form of prior treatment such as transsphenoidal resection, or craniotomy and
resection had been conducted. The others were deemed ineligible for microsurgery because of
body health or private choice, and MASEP GKRS served as the primary treatment modality.
Endocrinological, ophthalmological, and neuroradiological responses were evaluated.
Results: MASEP GKRS was tolerated well in these patients under the follow-up period ranged
from 60 to 90 months; acute radioreaction was rare and 17 patients had transient headaches with
no clinical significance. Late radioreaction was noted in 1 patient and consisted of consistent
headache. Of the 68 patients with adrenocorticotropic hormone-secreting(ACTH) adenomas,
89.7% showed tumor volume decrease or remain unchanged and 27.9% experienced normalization
of hormone level. Of the 176 patients with prolactinomas, 23.3% had normalization of hormone
level and 90.3% showed tumor volume decrease or remain unchanged. Of the 103 patients with
growth hormone-secreting(GH) adenomas, 95.1% experienced tumor volume decrease or remain
unchanged and 36.9% showed normalization of hormone level.
Conclusion: MASEP GKRS is safe and effective in treating secretory pituitary adenomas. None of
the patients in our study experienced injury to the optic apparatus or had other neuropathies
related with gamma knife. MASEP GKRS may serve as a primary treatment method in some or as
a salvage treatment in the others. However, treatment must be tailored to meet the patient's
symptoms, tumor location, tumor morphometry, and overall health. Longer follow-up is required
for a more complete assessment of late radioreaction and treatment efficacy.
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Pituitary adenomas are common lesions and represent
20% of all primary brain tumors[1,2]. The epidemiologi-
cal studies have demonstrated that nearly 20% of the gen-
eral population harbor pituitary adenomas[3,4]. Pituitary
adenomas are broadly classified into two groups[5]. In the
first category are those that secrete excess amounts of nor-
mal pituitary hormones and present with a variety of clin-
ical syndromes depending on the types of hormones
secreted. Meanwhile, some macroadenoma may present
with pressure symptoms, often increase in size if
untreated, and in some rare cases they may cause symp-
toms related to mass effect in which the optic nerves and
chiasm are compressed[6,7]. The second category of pitu-
itary adenomas is nonfunctioning adenomas that do not
secrete any known biologically active pituitary hormones.
Patients can also suffer hypopituitarism secondary to
compression of the normal functioning pituitary
gland[8].
In the treatment of pituitary adenomas the goal is to
remove the tumor mass or arrest further growth and when
present normalize hormonal hypersecretion. Transsphe-
noidal surgery is established as one of the most reliable
treatment modalities. This modern microsurgical tech-
nique can reduce tumor mass to protect surrounding
structures from potential compression, and achieve the
endocrinological cure of the symptoms caused by hor-
mone secreting tumors. Long term tumor control rates
after transsphenoidal excision alone vary from 50 to
80%[9]. However, in some cases, many patients are
already in poor physical condition caused by extended
production of the excess pituitary hormones, and general
anesthesia itself sometimes brings a certain risk for them.
Also, they often show invasion to surrounding structures
including cavernous sinus. And for these types of pituitary
adenomas, incomplete tumor resection or recurrence as a
result of tumor invasion into surrounding structures is
quite common[10].
In recent years, gamma knife radiosurgery(GKRS) has
emerged as an important treatment modality in the man-
agement of secretory pituitary adenomas with its high effi-
cacy. Radiosurgical treatment may deliver a high dose to
the adenomas with high accuracy and may not influence
the nearby neural structures to induce neurological
defect[11]. Recently, more and more reports have detailed
treatment results for secretory pituitary adenomas with
GKRS, and there have been a number of reports of GKRS
as a primary treatment for secretory pituitary adeno-
mas[12]. However, most results of these reports were
based on the gamma knife with radioactive source stati-
cally, and the time of the follow-up varied from months
to years. This article reviews our 10 years of clinical expe-
rience in performing rotary gamma knife in patients with
secretory pituitary adenomas. The focus of this research is
to define accurately the efficacy, safety, complications,
and role of rotary gamma knife for treatment of secretory
pituitary adenomas.
Methods
Characteristic of the patients
Between 1997 and 2007, 1681 patients with a diagnosis
of secretory pituitary adenoma were treated with MASEP
rotary gamma knife(MASEP instruments, Inc., Shenzhen,
P.R. China) in our medical center. The patients with secre-
tory pituitary adenoma treated in our studies are those
loss convenience, intolerant of or resistant to medical
therapies. Some of them were evaluated ineligible for neu-
rosurgery because of body health and the others rejected
to surgery on private choice or economic condition. 347
patients under medical therapies irregularly less than 3
months after MASEP GKRS and getting follow-up with at
least 60 months were taken in our study, and those with
follow-up less than 60 months or taken medical therapies
regularly after MASEP GKRS were excluded. Our study
population comprised 162 men (46.7%) and 185 women
(53.3%). Their age ranged from 17 to 86 years (mean
41.8). The patients presented with a 1- to 19-year history
(mean 2.7). In 47 of these patients some form of prior
treatment such as transsphenoidal resection, or craniot-
omy and resection had been conducted. The others were
deemed ineligible for microsurgery because of body
health or private choice, and MASEP GKRS served as the
primary treatment modality. Endocrinological, ophthal-
mological, and neuroradiological exams were taken for all
of them. The diagnosis was made on the basis of magnetic
resonance imaging (MRI) findings, endocrinological
exam findings, pathological findings (available for post-
operative patients), and their clinic history. Of these
patients treated, 68(19.6%) had a diagnosis of adrenocor-
ticotropic hormone-secreting adenomas, 176(50.7%) had
a diagnosis of prolactinomas, and 103(29.7%) had
growth hormone-secreting adenomas. The mean follow-
up period was 67.3 months (range 60~90 months) (Table
1).
Gamma knife processing
Patients were fixed in the Leksell stereotactic head frame
under administration of local anesthesia. Before treat-
ment, a high-resolution MRI with gadolinium-enhance-
ment to obtain precise information on the shape, volume,
and the three-dimensional coordinates of the tumors and
the surrounding anatomic structures is performed. Radio-
surgery was performed using the MASEP rotary gamma
knife. MASEP rotary gamma ray stereotactic extracranial
system is equipped with 25 Co-60 sources. Each source is
formed by certain amount of Φ1 × 1 cobalt granules
welded into 2 layer stainless steel casing through argon
fluorine welding technique to make it seal-tight. The totalPage 2 of 9
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(6500 Ci ± 10%). Source specific activity is 300 Ci/g.
Source active zone is Φ3.1 × 30. At initial loading the
water-absorption dose rate at focusing point is greater
than 3 Gy/min. 25 cobalt sources are placed in the colli-
mator passages. The commercially available software,
MASEP Gamma-Plan (MASEP instruments, Inc., Shen-
zhen, P.R. China) was used for complex dose planning.
The radiosurgical planning was done jointly by neurosur-
geons and radiation oncologists. Dose planning requires
delineation of the targets and the adjacent structures,
especially the optic chiasm. Though the MASEP gamma
knife has five collimator sizes, 4, 8, 14, 18 and 22 mm, the
4 mm and 8 mm collimator were used commonly. The
day before MASEP GKRS, patients were claimed to take
1.5 mg hexadecadrol. The day after MASEP GKRS, patients
were desired to take intervenous drop infusion of 250 ml
mannitol plus 10 mg hexadecadrol (twice a day) for 3
days to avoid radioreaction. Then they were discharged
and could return to their daily lives without any neurolog-
ical deterioration.
Treatment planning
Tumor volume was 0.8~21.5 cm3(mean 5.2 cm3). For the
purpose of both growth control and hormonal remission,
secretory pituitary adenomas were usually irradiated more
than 12 Gy (range 12~35 Gy) at the tumor margin. The
whole tumor was covered within 50~70% isodose lines.
The dosimetric goal in every case was complete tumor cov-
erage. The prescribed marginal dose had to be decreased
occasionally to keep the dose less than 10 Gy to the optic
nerve, chiasma, and tract to avoid radiation-induced vis-
ual disturbances, less than 12 Gy to the brainstem and less
than 25 Gy to the internal carotid artery (Table 2).
Clinical observation
After the treatment of MASEP GKRS, follow-up was sched-
uled at intervals of 6 months, 1 year and annually thereaf-
ter. The visit routinely assessed the change in symptoms
after treatment, endocrinological examination and neuro-
radiological study.
In our series to evaluate ACTH-producing pituitary adeno-
mas, we utilized the 24 h urine cortisol collection not
excess of 200 μg/dL (550 nmol/dL) and the plasma corti-
sol level less than 2.5 μg/dL (69 nmol/dL) as the criteria
for endocrinological evaluation. For patients treated with
prolactinomas, we used normal serum prolactin level for
gender as cure criteria and the normal PRL range for non-
pregnant women is <500 mU/L (20 μg/L) and for men
<300 mU/L (12 μg/L). Meanwhile, we used the guidelines
for a remission or cure as the GH level less than 1 ng/
ml(2.5 mU/L) after glucose ingestion and a normal serum
type-1 insulin like growth factor(IGF-1) when matched
for age and gender to define the results of radiosurgery for
patients with acromegaly.
After irradiation of pituitary tissue, regular surveillance is
needed to detect development of hypopituitarism, partic-
ularly GH deficiency. Basal pituitary profiles, including
Table 1: Characteristics of patients with pituitary adenomas 
treated with MASEP GKRS
Characteristic Value(%)




Mean age(yrs) 41.8 (range17~86)
Mean history(yrs) 2.7(range1 to 19)
No. of previous treatments
transsphenoidal resection 27*
craniotomy and resection 23
Mean follow-up after GKRS(mos) 67.3 (range 60~90)
Type of adenomas
ACTH adenomas 68(19.6)
microadenoma(size, cm3) 21 (0.8~1.1)







*three patient had performed repeated craniotomy and resection
Table 2: MASEP GKRS plan for patients with pituitary adenomas(mean)
Type Cases Margin dose(Gy) Treatment isodose(%) Tumor coverage(%)
ACTH 68
microadenoma 21 15~28(18.9) 50 100
macroadenoma 47 18~35(24.9) 50~70(54.7) 70~100(95.3)
PRL 176
microadenoma 0 0 0 0
macroadenoma 176 15~35 (22.4) 50~70(55.3) 64~100(93.3)
GH 103
microadenoma 0 0 0 0
macroadenoma 103 12~30 (21.4) 50~70(57.6) 55~100(88.6)Page 3 of 9
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mone, IGF-1 and assessment for the clinical features of
GH deficiency or consequent gonadal failure, were per-
formed regularly on follow-up.
The statistical analysis
Statistical analysis was performed with the aid of commer-
cially available software (StatView 4.5.1; Abacus Con-
cepts, Inc., Berkeley, CA).
Results
MASEP GKRS was tolerated well in these patients. Acute
radioreaction was rare and 17 patients had transient head-
aches with no clinical significance. Consistent headache
was noted in 1 patient 4 years after radiosurgery and per-
sisted for the entire 1 year during follow-up. There was no
significant compression and the reason of headache was
still unknown. Of the 68 patients with ACTH adenomas,
61(89.7%) showed tumor volume decrease or remain
unchanged and 19(27.9%) experienced normalization of
hormone level (Figure 1 and Figure 2). Of the other 5
patients with enlarged ACTH adenomas, 4 had repeated
MASEP GKRS. One had craniotomy and resection of the
mass after experiencing consistent vomiting. Another two
cases with no clinical symptom with a neuroradiological
diagnosis of radiation necrosis received no more treat-
ment. Of the 176 patients with prolactinomas, 41(23.3%)
had normalization of hormone level and 159(90.3%)
showed tumor volume decrease or remain unchanged
(Figure 3 and Figure 4). Of the 12 patients with enlarged
prolactinomas, 9 had repeated GKRS. Two had transsphe-
noidal resection of the mass after experiencing consistent
headache. One case died 4 years after primary MASEP
GKRS rejecting any medical intervention. Another 5 cases
with the diagnosis of radiation necrosis had no clinical
symptoms and lived as usual. Of the 103 patients with GH
adenomas, 98(95.1%) experienced tumor volume
decrease or remain unchanged and 38(36.9%) showed
normalization of hormone level (Figure 5 and Figure 6).
Of the other 3 patients with enlarged GH adenomas, 2
had repeated MASEP GKRS. One had craniotomy and
resection of the mass after experiencing consistent vomit-
ing. Another 2 cases with no clinical treatment had a neu-
roradiological diagnosis of radiation necrosis and were
under observation.
Typical MRI scan changes in ACTH adenomaFigure 1
Typical MRI scan changes in ACTH adenoma. Coronal 
T1-weighted postcontrast MRI scan at left and right, obtained 
in Patient 1, a 30-year-old man who presented with ACTH 
adenomas and consistent headache 2 years before undergo-
ing GKRS. An enhancing mass lesion is seen in the sella turcia 
with extension to bilateral internal carotid artery. Patient 1's 
serum ACTH level was 381.6 pg/ml, and his blood pressure 
was over 180/120 mmHg. The patient was treated with 
MASEP GKRS, and MRI was performed for treatment plan-
ning. 26 Gy defined to the 50% isodose line is used to cover 
the full extent of the pituitary tumor in all three planes.
Typical MRI scan changes in ACTH adenomaFigure 2
Typical MRI scan changes in ACTH adenoma. No 
enhancing mass lesion is seen in the sella turcia under the T1-
weighted postcontrast MRI scan performed 2 years after 
GKRS. Patient 1's clinical symptom did improve. His serum 
ACTH level came down to 40.4 pg/ml, and his blood pres-
sure was controlled within 140/80 mmHg.Page 4 of 9
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inations were available in all these patients. The data col-
lected as of the end of 2007 are summed up in table 3 and
table 4.
Overall 91.6% of tumor control was achieved in 318 with
only mild and transient neurological complications in
some cases. 28.2% of normalization of hormone level rate
and 61.1% of decrease of hormone level rate were also
achieved. Hypopituitarism occurred in 6(1.7%) patients
who received replacement therapy now.
Discussion
There are multiple treatment modalities for pituitary ade-
nomas. The individual treatment must be tailored to a
patient's symptoms, overall health, and tumor morphom-
etry. GKRS has been found to be an effective, noninvasive
method for treating patients with functioning pituitary
adenoma as a complement to the surgery. Tumors that
compress the optic pathway should be removed with
microsurgery, and residual tumor, especially in the cav-
ernous sinus, is a good indication for radiosurgery. At our
institute, MASEP GKRS may be considered as an alterna-
tive treatment to microsurgery if patients are reluctant to
undergo surgical resection, or are unable to undergo
microsurgery under general anesthesia because of old age
or poor medical conditions. The purpose of GKRS, in the
case of secretory pituitary adenomas, is to control tumor
growth and normalize endocrinological hypersecretion.
Secretory adenomas seem to require a higher radiation
dose than nonfunctioning pituitary adenomas[13]. Ganz
suggested that the effective dose for secretory adenomas
should be higher than 25 Gy according to the details[14].
Laws and Vance estimated that a higher percentage of con-
trol of hyper-functioning syndromes could be accom-
plished with the higher margin dose[15]. The lowest
effective radiation dose in our study was 12 Gy delivered
to the tumor margin; the mean marginal dose was 22.2
Gy. According to our experience, the suitable margin dose
Typical MRI scan changes in prolactinomas adenomaFigure 3
Typical MRI scan changes in prolactinomas adenoma. 
Coronal T1-weighted postcontrast MRI scan at left and right, 
obtained in Patient 2, a 27-year-old woman who presented 
with prolactinomas adenomas and amenorrhea-galactorrhea 
4 years before undergoing MASEP GKRS. An asymmetrically 
enhancing mass lesion is seen in the sella turcia with exten-
sion to bilateral internal carotid artery. Patient 2's serum 
prolactin level was 183.7 ng/ml. The patient was treated with 
MASEP GKRS twice because of the huge volume of the mass. 
The second MASEP GKRS was performed 1 year after the 
first one. The tumor was treated separately with the lower 
and upper part in order to protect the optic chiasma. MRI 
was performed for treatment planning. 25 Gy defined to the 
50% isodose line is used to cover the lower part of the pitui-
tary tumor in the first treatment, and 18 Gy defined to the 
50% isodose line is used to cover the upper part of the pitui-
tary tumor in the second time.
Typical MRI scan changes in prolactinomas adenomaFigure 4
Typical MRI scan changes in prolactinomas adenoma. 
An enhancing mass lesion is seen in the sella turcia under the 
T1-weighted postcontrast MRI scan performed 1 year after 
MASEP GKRS, but the volume of the mass had collapsed for 
more than 50%. Patient 2's clinical symptom did improve. 
Her serum prolactin level came down to 14.5 ng/ml, and she 
got gestation and delivered a healthy baby recently.Page 5 of 9
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:36 http://www.jeccr.com/content/28/1/36should depend on the endocrinological type of the secre-
tory pituitary adenoma. However, the recent report of Pol-
lock for functioning adenomas revealed the radiation
dose was not related to endocrinological outcome[16].
In nearly all published series, stereotactic radiosurgery
afforded excellent control of tumor growth. Hayashi
reported that the tumor control rate for pituitary adenoma
after GKRS was between 93% and 94%, and that the
tumor shrinkage rate ranged from 46% to 56.7%[17].
Many studies reported a greater than 95% control of
tumor size with follow-up varying from months to
years[18,19]. Some series have even demonstrated
improvement in visual function following radiosurgery
upon shrinkage of the tumor. Most pituitary adenomas
tend to be slow growing lesions. As such, it may be mis-
leading to evaluate series of patients with relatively short
follow-up. In our previous study, the effects of MASEP
GKRS may get stable within three years after the treat-
ment, and this study shows concordant results within the
follow-up more than 5 years.
At the time when GKRS started, the results of microsurgery
were disappointing regarding ACTH-producing pituitary
adenomas and the role of GKRS as primary therapy was
evaluated. We have not seen any recurrences after MASEP
GKRS in patients who obtained remission in contrast to
pituitary microsurgery with progressive increase of recur-
rences of Cushing's syndrome with time. Cushing's dis-
ease is a serious catabolic illness that requires rapid
normalization of cortisol hypersecretion. Thus pituitary
microsurgery is the primary treatment for Cushing's dis-
ease; gamma knife surgery can be applied when open sur-
gery is contraindicated or refused or as a secondary
treatment when open surgery has failed or the tumor
extends into the cavernous sinuses. Many series utilized
the 24 h urine cortisol collection as part of the criteria for
endocrinological evaluation, and the endocrinologi-
cal'cure'rates ranged from 17 to 83%[20,21]. In a recent
review, Laws and Vance reported remission in about 60%
of their patients with Cushing's disease followed for more
than 6 months with a mean time to remission of approx-
Typical MRI scan changes in GH adenomaFigure 5
Typical MRI scan changes in GH adenoma. Coronal 
T1-weighted postcontrast MRI scan at upper left and right, 
obtained in Patient 3, a 33-year-old man who presented with 
GH adenomas and acromegaly 7 years before undergoing 
MASEP GKRS. (Figure 5) An enhancing mass lesion is seen in 
the sella turcia with extension into the left cavernous sinus. 
Patient 3's serum growth hormone level was 497.3 ng/ml ini-
tially. He was treated with transsphenoidal surgery, and the 
tumor relapsed shortly with the serum growth hormone 
level reduced to 130.2 ng/ml. The patient was treated with 
MASEP GKRS, and MRI was performed for treatment plan-
ning. 20 Gy defined to the 50% isodose line is used to cover 
the full extent of the pituitary tumor in the first radiosurgery, 
and 28 Gy defined to the 50% isodose line is used to cover 
the pituitary tumor in the second time one year later.
Typical MRI scan changes in GH adenomaFigure 6
Typical MRI scan changes in GH adenoma. No signifi-
cantly enhancing mass lesion is seen in the sella turcia under 
the T1-weighted postcontrast MRI scan performed 1 year 
after the second MASEP GKRS. Patient 3's clinical symptom 
did improve. His serum growth hormone level was lower 
than 10 ng/ml.Page 6 of 9
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complement to open surgery[22]. In this research, we
observed similar result in our patients with radiosurgery
as the major treatment.
As most patients with prolactinomas can be adequately
controlled by medical treatment. Gamma knife radiosur-
gery has been used by us in only few patients. It may be a
suitable alternative in patients who experience side effects
of dopaminergic drugs or in patients with tumor exten-
sion to the cavernous sinuses. The largest series of prolac-
tinomas treated with GKRS was reported by Pan et al[23].
Their study used normal serum prolactin level for gender
as cure criteria, and they reported a 15% endocrinological
remission rate achieved for 128 patients with a median
follow-up of 33 months. Some studies utilize relatively
similar criteria. 'Cure'rates varied from 20 to 84%. In our
study, we achieved better tumor growth control than
endocrinological control without the use of medical ther-
apies after radiosurgery, and the usage of medical thera-
pies after radiosurgery still needed further evaluation. Pan
et al suggested that dopaminergic drugs seemed to induce
radioprotection[23]. In our unit, MASEP GKRS were per-
formed during an intermission in drug therapy when the
drug therapy is discontinued.
The criteria for controlling acromegaly have still been
inconsistent. The most widely accepted guidelines for a
remission in acromegaly consist of a GH level less than 1
ng/ml in response to a glucose challenge and a normal
serum IGF-1 when matched for age and gender. Some
studies with such criteria detail the results of GKRS for
patients with acromegaly. The mean radiosurgery margin
doses in these series ranged from 15 to 34 Gy. 'Cure'rates
following radiosurgery varied from 0 to 100%. In these
series with at least 16 patients and a median follow-up of
2 years, endocrinological remission rates ranged from 20
to 96%[24,25]. Our study found similar results with
longer follow-up. The high incidence of hypopituitarism
is one of the significant shortcomings of conventional
Table 3: Neuroradiological changes of patients with pituitary adenomas treated with MASEP GKRS
Type of adenomas collapse unchanged enlarge enlarged with necrosis
ACTH adenomas
microadenoma 5 14 2 0
macroadenoma 23 19 3 2
Prolactinomas
microadenoma 0 0 0 0
macroadenoma 97 62 12 5
GH adenomas
microadenoma 0 0 0 0
macroadenoma 56 42 3 2
Total(%) 181(52.1) 137(39.5) 20(5.8) 9(2.6)
4 patients with ACTH adenomas had repeated MASEP GKRS; 12 patients with prolactinomas had repeated MASEP GKRS; 2 patients with GH 
adenoma had repeated MASEP GKRS
Table 4: Endocrinological changes of patients with pituitary adenomas treated with MASEP GKRS
Type of adenomas normalization decrease no improve hypopituitarism
ACTH adenomas
microadenoma 7 11 2 1
macroadenoma 12 31 4 0
Prolactinomas
microadenoma 0 0 0 0
macroadenoma 41 114 18 3
GH adenomas
microadenoma 0 0 0 0
macroadenoma 38 56 7 2
Total(%) 98(28.2) 212(61.1) 31(8.9) 6(1.7)
Hypopituitarism occurred in 1 patients with ACTH adenomas after MASEP GKRS; 3 patients with prolactinomas had hypopituitarism after MASEP 
GKRS; 2 patient with GH adenoma had hypopituitarism after MASEP GKRSPage 7 of 9
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tion. The data available are varied, depending on the
length of follow-up. Tsang reported more than 22% of
patients developing hypopituitarism during the 10 years
after conventional irradiation[27]. Salinger reported 37%
of patients developing hypopituitarism, within a follow-
up of 5 years[28]. Stereotactic targeting, allowed by GKRS,
should lower the incidence of hypopituitarism. However,
the incidence of hypopituitarism after GKRS is difficult to
determine at present. Reports in the literature for the inci-
dence of post-radiosurgery hypopituitarism vary widely.
Well respected groups have reported a low incidence
(0~36%) of pituitary dysfunction following radiosur-
gery[29]. A long term study from the Karolinska Institute
with a mean follow-up of 7 years, however, reported an
eventual 42% incidence of hypopituitarism[30]. Post
found that hypopituitarism following radiosurgery corre-
lated with the radiation dose to the pituitary stalk[31].
The difficulty with determining the exact incidence of
radiosurgery-induced hypopituitarism stems in part from
the fact that many of the patients have already undergone
previous radiation therapy or surgery. In addition, pitui-
tary deficiencies may result in part from normal aging.
Thus, it is likely that hypopituitarism in the post-radiosur-
gical population is multifactorial in etiology and related
to radiosurgery as well as to age-related changes and pre-
vious treatments. However, in 347 patients with secretory
pituitary adenomas treated, only 1.7% patients developed
hypopituitarism. The MASEP rotary gamma knife may
make an important contribution to this result. The 25 60-
Co sources were all rotating during the whole treatment
process and the healthy pituitary stalk received much less
dose of irradiation than in the radiosurgery with tradi-
tional static gamma knife. We proposed that the dose of
irradiation on pituitary tissue may be the most important
cause of hypopituitarism. Kokubo reported the similar
findings[32].
Conclusion
In summary, MASEP GKRS can be an effective method for
controlling tumor growth and inducing hormonal nor-
malization in patients with functioning pituitary. The
treatment is safe with low mortality and morbidity. Com-
plications from the optic apparatus have not been found
when the dose to that area is below 10 Gy. Brain necrosis,
neuropsychological disturbances and secondary brain
tumors have not been found with gamma knife radiosur-
gery. The incidence of post-radiosurgery hypopituitarism
is very low and the development of hypopituitarism fol-
lowing radiosurgery can be avoided by observing the max-
imum mean dose on healthy peritumoral pituitary of 15
Gy according to our experience. In our treatment, the
rotary gamma knife is proved to be as safety and efficient
as the static gamma knife. Long-term follow up after
MASEP GKRS for control of pituitary function is still
needed even when the patient is in remission due to the
risk of late occurring pituitary insufficiency.
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